HIC
PACB icon

Hartline Investment Corp’s Pacific Biosciences PACB Stock Holding History

Hartline Investment Corp’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$116K Hold
69,000
– – 0.01% 114
2026
Q1 		$91.1K Buy
69,000
+38,000
+123% +$68K 0.01% 111
2025
Q4 		$58K Hold
31,000
– – 0.01% 108
2025
Q3 		$39.7K Hold
31,000
– – ﹤0.01% 113
2025
Q2 		$38.4K Hold
31,000
– – ﹤0.01% 103
2025
Q1 		$36.6K Buy
+31,000
New +$47.6K ﹤0.01% 100

Other funds holding PACB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Hartline Investment Corp's PACB Position: Q2 2026 in Review

Hartline Investment Corp held its Pacific Biosciences (PACB) position steady in Q2 2026 at 69,000 shares worth $116K. The position accounts for 0.01% of the portfolio, ranked #114.

Hartline Investment Corp first reported a position in PACB in Q1 2025 and has held it in 6 quarters since. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

  • Hartline Investment Corp held 69,000 shares of Pacific Biosciences worth $116K as of Q2 2026.
  • Hartline Investment Corp left its Pacific Biosciences share count unchanged in Q2 2026.
  • Pacific Biosciences made up 0.01% of Hartline Investment Corp's portfolio in Q2 2026, its #114 holding.
  • Hartline Investment Corp first reported a position in Pacific Biosciences in Q1 2025 and has held it in 6 quarters since.
  • 223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Hartline Investment Corp's 13F filing for Q2 2026, filed 29 Jul 2026.